Jefferies Financial Group Inc. Takes $348,000 Position in Zenas BioPharma, Inc. (NASDAQ:ZBIO)

Key Points

• Jefferies Financial Group Inc. acquired 44,067 shares of Zenas BioPharma, valued at approximately $348,000, during the first quarter.
• Zenas BioPharma's stock experienced a decline of 1.1%, trading at $14.63, with a fifty-two week low of $5.83 and a high of $26.25.
• Analysts have set new price targets for ZBIO, with Wedbush issuing a $35.00 target and HC Wainwright setting a target of $30.00.

Jefferies Financial Group Inc. bought a new position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 44,067 shares of the company's stock, valued at approximately $348,000. Jefferies Financial Group Inc. owned about 0.11% of Zenas BioPharma as of its most recent SEC filing.

Separately, New York State Common Retirement Fund purchased a new stake in Zenas BioPharma during the first quarter worth approximately $49,000.

Zenas BioPharma Stock Performance

NASDAQ ZBIO traded up $0.05 on Tuesday, reaching $14.96. The stock had a trading volume of 20,984 shares, compared to its average volume of 180,741. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $26.25. The company's 50-day moving average is $12.21. The firm has a market capitalization of $625.78 million and a PE ratio of -4.21.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The firm had revenue of $10.00 million during the quarter, compared to analysts' expectations of $5.00 million.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ZBIO shares. Wedbush restated an "outperform" rating and set a $35.00 target price on shares of Zenas BioPharma in a research note on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Zenas BioPharma in a research note on Friday, May 16th.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.